About Viking Therapeutics (NASDAQ:VKTX)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$0.40 per share
Price / Book17.30
Return on Equity-330.42%
Return on Assets-144.29%
Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions
What is Viking Therapeutics' stock symbol?
Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."
How were Viking Therapeutics' earnings last quarter?
Viking Therapeutics Inc (NASDAQ:VKTX) announced its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.03. View Viking Therapeutics' Earnings History.
When will Viking Therapeutics make its next earnings announcement?
Where is Viking Therapeutics' stock going? Where will Viking Therapeutics' stock price be in 2018?
3 analysts have issued 1-year target prices for Viking Therapeutics' stock. Their forecasts range from $6.00 to $8.00. On average, they anticipate Viking Therapeutics' stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Viking Therapeutics.
Are investors shorting Viking Therapeutics?
Viking Therapeutics saw a increase in short interest during the month of January. As of January 12th, there was short interest totalling 1,965,269 shares, an increase of 48.1% from the December 29th total of 1,326,621 shares. Based on an average daily volume of 833,219 shares, the short-interest ratio is presently 2.4 days. Approximately 8.1% of the shares of the company are short sold.
Who are some of Viking Therapeutics' key competitors?
Some companies that are related to Viking Therapeutics include CymaBay Therapeutics (CBAY), Reata Pharmaceuticals (RETA), NuCana (NCNA), G1 Therapeutics (GTHX), Aclaris Therapeutics (ACRS), Five Prime Therapeutics (FPRX), Fate Therapeutics (FATE), Keryx Biopharmaceuticals (KERX), Insys Therapeutics (INSY), Coherus Biosciences (CHRS), Rigel Pharmaceuticals (RIGL), Omeros (OMER), Obseva (OBSV), ZIOPHARM Oncology (ZIOP), Stemline Therapeutics (STML), Cascadian Therapeutics (CASC), Arrowhead Pharmaceuticals (ARWR) and Aduro BioTech (ADRO).
Who are Viking Therapeutics' key executives?
Viking Therapeutics' management team includes the folowing people:
- Lawson Macartney Ph.D., Chairman of the Board (Age 57)
- Brian W. Lian Ph.D., President, Chief Executive Officer, Director
- Michael Morneau, Chief Financial Officer (Age 49)
- Amy Broidrick, Senior Vice President - Corporate Development
- Gregory S. Zante CPA, Vice President - Finance and Operations (Age 42)
- Catherine Lee Kelleher M.D., Vice President - Clinical Development
- Matthew W. Foehr, Director (Age 44)
- Charles A. Rowland Jr., Director (Age 59)
- Matthew Singleton, Independent Director
- Stephen W. Webster, Independent Director (Age 56)
When did Viking Therapeutics IPO?
(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.
Who owns Viking Therapeutics stock?
Viking Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Sphera Funds Management LTD. (4.56%), Renaissance Technologies LLC (1.92%), Millennium Management LLC (1.49%), EAM Investors LLC (1.33%), Park West Asset Management LLC (1.28%) and Opaleye Management Inc. (1.06%). View Institutional Ownership Trends for Viking Therapeutics.
Who bought Viking Therapeutics stock? Who is buying Viking Therapeutics stock?
Viking Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Millennium Management LLC, EAM Investors LLC, Renaissance Technologies LLC, Opaleye Management Inc., Park West Asset Management LLC, Iguana Healthcare Management LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Viking Therapeutics.
How do I buy Viking Therapeutics stock?
Shares of Viking Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viking Therapeutics' stock price today?
One share of Viking Therapeutics stock can currently be purchased for approximately $6.92.
How big of a company is Viking Therapeutics?
Viking Therapeutics has a market capitalization of $326.05 million. The biotechnology company earns $-14,730,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Viking Therapeutics employs 12 workers across the globe.
How can I contact Viking Therapeutics?
Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]
MarketBeat Community Rating for Viking Therapeutics (VKTX)MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Viking Therapeutics (NASDAQ:VKTX) Earnings History and Estimates Chart
Viking Therapeutics (NASDAQ VKTX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Viking Therapeutics (NASDAQ:VKTX) Earnings Estimates
Current Year EPS Consensus Estimate: $-0.86 EPS
Next Year EPS Consensus Estimate: $-0.68 EPS
Dividend History for Viking Therapeutics (NASDAQ:VKTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Viking Therapeutics (NASDAQ VKTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.60%
Institutional Ownership Percentage: 11.72%
Viking Therapeutics (NASDAQ VKTX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/15/2016||Matthew W Foehr||Director||Buy||13,000||$1.21||$15,730.00||39,250|| |
|4/13/2016||Matthew W Foehr||Director||Buy||20,000||$1.24||$24,800.00||26,250|| |
Viking Therapeutics (NASDAQ VKTX) News Headlines
Viking Therapeutics (NASDAQ:VKTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Viking Therapeutics (NASDAQ:VKTX) Income Statement, Balance Sheet and Cash Flow Statement
Viking Therapeutics (NASDAQ VKTX) Stock Chart for Saturday, February, 24, 2018